Results 111 to 120 of about 13,117,018 (331)

Recombinant activated factor VII for uncontrolled bleeding postcardiac surgery

, 2016
Aly Makram Habib, Ahmed Yehia Mousa, Zohair Al‐Halees   +2 more
openalex   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

Recombinant Activated Factor VII in Aortic Surgery for Patients Under Hypothermic Circulatory Arrest

, 2022
Hayato Ise, Ryohei Ushioda, Hirotsugu Kanda, Fumiaki Kimura, Yasuaki Saijo, Payam Akhyari, Artur Lichtenberg, Hiroyuki Kamiya   +7 more
openalex   +1 more source

Recombinant-activated factor VII as hemostatic therapy in eight cases of severe hemorrhage from esophageal varices [PDF]

, 2004
Rafael Romero-Castro
openalex   +1 more source

Women with congenital factor VII deficiency: clinical phenotype and treatment options from two international studies

Haemophilia, 2016
M. Napolitano, M. D. Minno, A. Bátorová, A. Dolce, M. Giansily-Blaizot, J. Ingerslev, J. Schved, G. Auerswald, G. Kenet, G. Kenet, M. Karimi, T. Shamsi, A. R. Saez, R. Dolatkhah, A. Chuansumrit, M. Bertrand, G. Mariani   +16 more
semanticscholar   +1 more source

Crucial parameters for precise copy number variation detection in formalin‐fixed paraffin‐embedded solid cancer samples

Molecular Oncology, EarlyView.
This study shows that copy number variations (CNVs) can be reliably detected in formalin‐fixed paraffin‐embedded (FFPE) solid cancer samples using ultra‐low‐pass whole‐genome sequencing, provided that key (pre)‐analytical parameters are optimized.
Hanne Goris, Vasiliki Siozopoulou, Léon C van Kempen, Anne Sieben, Ella Roelant, Stig Hellemans, Elyne Backx, Laure Sorber, Koen De Winne, Senada Koljenović, Karen Zwaenepoel   +10 more
wiley   +1 more source

Déficit de factor VII. Reporte de dos casos en el Servicio de Hematooncología Pediátrica del Hospital Universitario San Ignacio

Revista Universitas Medica, 2010
La deficiencia del factor VII es una enfermedad hemorrágica rara, causada por la disminución o ausencia de este factor de la coagulación; menos de 200 casos se han reportado desde que se describió por primera vez en 1951.
ANGÉLICA ÁLVAREZ, JULIA MÁRQUEZ, JHAIR VARGAS, MARTHA VIZCAÍNO, ILIANA DE LOS REYES, CAROLINA GUZMÁN   +5 more
doaj  

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

Recombinant activated coagulation factor VII in the treatment of massive obstetric hemorrhage (literature review)

, 2014
Т. А. Федорова, E. V. Strelnikova   +1 more
openalex   +2 more sources

PREGNANCY AND FACTOR VII [PDF]

British Journal of Haematology, 1992
A R, Hubbard, L J, Parr, M G, Baines
openaire   +2 more sources